РАСПРОСТРАНЕННЫЙ АТЕРОСКЛЕРОЗ В ОБЩЕТЕРАПЕВТИЧЕСКОЙ ПРАКТИКЕ: НА ПУТИ К ОПТИМИЗАЦИИ ТАКТИКИ ВЕДЕНИЯ


Цитировать

Полный текст

Аннотация

Обсуждаются современные подходы к раннему выявлению доклинических маркеров распространенного атеросклероза и ведению этой категории больных. Подчеркивается, что доступные сегодня инструментальные методы ранней доклинической диагностики атеросклеротического поражения основных сосудистых бассейнов приобретают особое значение с точки зрения своевременной оптимизации терапевтической стратегии. Максимальное использование возможностей лечения подразумевает в т. ч. применение у этих больных ингибиторов АПФ и пентоксифиллина.

Об авторах

V V Fomin

Виктор Викторович Фомин

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

Список литературы

  1. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов // Системные гипертензии. 2010. № 3. С. 5-26.
  2. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-69.
  3. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-37.
  4. Burke G, Evans G, Riley W, et al. Arterial wall thickness is associated with prvalent cardiovascular diseases in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386-91.
  5. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994;25:2377-83.
  6. Duncan BB, Metcalf P, Crouse JR, et al. Risk factors differ for carotid artery plaque with and without acoustic shadowing. Atherosclerosis Risk in Communities Study Investigators. J Neuroimaging 1997;7:28-34.
  7. Stevens J, Tyroler HA, Cai J, et al. Body weight change and carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1998;147:563-73.
  8. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:478-87.
  9. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
  10. Ogata T, Yasaka M, Yamagishi M, et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005;24:469-74.
  11. Shammas NW. Epidemiology, classification and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3(2):229-94.
  12. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49.
  13. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-86.
  14. Dieter RS, Tomasson J, Gudjonsson T, et al. Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 2003;8(4):233-36.
  15. Criqui MH, Ninomiya JK, Wingard D, et al. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008;52(21):1736-42.
  16. Moussa ID, Jaff MR, Mehran R, et al. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter Cardiovasc Interv 2009;73(6):719-24.
  17. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45(6):1185-91.
  18. Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis 2009;102(8-9):625-31.
  19. Mourad JJ, Cacoub P, Collet JP, et al.; ELLIPSE scientific committee and study investigators. Screening of unrecognized peripheral arterial disease (PAD) using ankle brachial index in high cardiovascular risk patients free from symptomatic PAD. J Vasc Surg 2009;50(3):572-80.
  20. Jaar BG, Plantinga LC, Astor BC, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis 2007;14(3):304-13.
  21. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000;35(1 Pt. 2):353-59.
  22. Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008;215(3):273-79.
  23. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997;15(11):1295-302.
  24. Lonn E, Yusuf S, Dzavik V, et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-25.
  25. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2009;(4):CD003075.
  26. Kokesh J, Kazmers A, Zierler RE. Pentoxifylline in the nonoperative management of intermittent claudication. Ann Vasc Surg 1991;5(1):66-70.
  27. Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. Curr Vasc Pharmacol 2009;7(3):394-413.
  28. Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007;192(2):313-22.
  29. Chen YM, Wu KD, Tsai TJ, et al. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31(4):773-83.
  30. Maiti R, Agrawal NK, Dash D, et al. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 2007;47(2-3):118-24.
  31. Fernandes JL, de Oliveira RT, Mamoni R. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo controlled study. Atherosclerosis 2008;196(1):434-42.
  32. Жданова И.В., Цвиренко С.В., Барац С.С. и др. Влияния флувастатина и его комбинации с аспирином и тренталом на гемостаз и микроциркуляцию при атеросклерозе // Терапевтический архив. 2002. № 74(8). С. 9-12.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах